Abstract Library

#4505 NET-IMPRESS: A novel methylation-based assay to diagnose and monitor NET patients using liquid biopsies

Introduction: Previously, we showed that analysing copy number alterations (CNAs) in cell-free DNA (cfDNA) of NET patients using shallow whole genome sequencing (sWGS) is a potential biomarker for diagnosis and follow-up (PMID: 34759042). We now present NET-IMPRESS, an easy, cost-effective methylation-based assay for detecting circulating tumour DNA (ctDNA) in NET samples.

Conference:

Presenting Author:

Authors: Mariën L, Ibrahim J, de Meulenaere N, Chhajlani S, Neefs I,

Keywords: neuroendocrine tumour, liquid biopsy, DNA methylation, copy number alterations, biomarker selection, IMPRESS technology,

#4380 Cell-free DNA concentration correlates with copy number variant (CNV)-count, describes tumour progression and nuclear instability in GEP-NETs

Introduction: Cell-free DNA (cfDNA) levels depend on various factors related to the shedding of cells and might provide valuable information on tumour state and treatment success. In a genomic profiling pilot study conducted as part of the COMPOSE Phase III multicentre open-labelled clinical trial we assessed multiple factors and their impact on cfDNA levels in 14 GEP-NET patients.

Conference:

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Capdevila J, Smutna V, Weckwerth W, Erdoe M,

Keywords: CNV, cfDNA, liquid biopsy, quantitative marker, cfDNA concentration, longitudinal, GEP-NET, genomic profiling,

#4244 Cell-free DNA (cfDNA) methylation profiling for minimally invasive cancer detection in patients with Extra-Pulmonary NeuroEndocrine Carcinoma (EP-NEC)

Introduction: Robust biomarkers to aid clinical management of patients (pts) with EP-NEC are lacking. cfDNA methylation profiling has shown higher sensitivity/specificity than cfDNA genome profiling in diagnosing and classifying various cancers, including Small Cell Lung Cancer (SCLC).

Conference:

Presenting Author: Frizziero M

Authors: Frizziero M, Pearce S, Clipson A, Rothwe D, Mouliere F,

Keywords: Extra-Pulmonary NeuroEndocrine Carcinoma, cfDNA, methylation profililing, biomarker,

#4147 5-Hydroxymethylcytosine profiling of plasma-derived circulating free DNA in patients with pancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

Introduction: Cell-free DNA (cfDNA) 5-hydroxymethylcystosine (5hmC) analysis, a novel epigenomic technology, can detect changes in tumor gene expression and regulation in liquid biopsies.

Conference:

Presenting Author:

Authors: Sponheim J, Wong C, Thiis-Evensen E, Coruh C, Ning Y,

Keywords: [177Lu]Lu-DOTA-TATE, Lutathera, Peptide Receptor Radionuclide Therapy, Radioligand Therapy, Pancreatic Neuroendocrine Tumor, Biobank, 5-Hydroxymethylation,

#4139 Characterisation of new biomarkers from patients with neuroendocrine cancer using liquid biopsy methods

Introduction: Neuroendocrine tumors originate from neuroendocrine cells. Clinicians diagnose and track these tumors not only but also by analysing patients' blood for biomarkers. Including liquid biopsy in early detection and monitoring can improve patient outcomes.

Conference:

Presenting Author:

Authors: Pachnikova G, Jann H, Tacke F, Keilholz U,

Keywords: liquid biopsy, circulating tumor cells, cell-free DNA, neuroendocrine tumor, case study, copy number variations,